Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Are The Market Size Estimates For The Gabapentin Market?

In recent years, the gabapentin market has experienced significant growth. The market value, which is projected to rise from $2.78 billion in 2024 to $3.01 billion in 2025, is expected to maintain a compound annual growth rate (CAGR) of 8.5%. This substantial growth during the historical period is a result of various factors such as an increased prevalence of epilepsy, a surge in neuropathic pain cases, heightened awareness about neurological disorders, an aging population, and an increase in the use of generic anticonvulsants.

The gabapentin market is projected to experience significant expansion in the forthcoming years, with a growth trajectory setting the market value at $4.12 billion by 2029, computed at a compound annual growth rate (CAGR) of 8.2%. The surge anticipated during the forecast period is credited to factors such as the escalating demand for chronic pain management, increased approvals of gabapentin concoctions, improved healthcare access in burgeoning regions, a heightened emphasis on personalized medicine, and growing burden of neurological disorders. The forecast period is also likely to see predominant trends like enhancement in drug delivery mechanisms, the inclusion of gabapentin in combination therapies, tech-infused research and development aimed at neuropathic pain, progression in extended-release formulations, and breakthroughs in pharmacogenomics applications.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24544&type=smp

Which Industry Forces Are Driving The Gabapentin Market Forward?

The escalating occurrence of epilepsy is anticipated to fuel the expansion of the gabapentin market in the future. Epilepsy, a neurological disorder marked by recurrent seizures due to abnormal electrical activity in the brain, is seeing a surge primarily owing to an aging population. The likelihood of neurological afflictions sparking seizures increases with advanced age. Gabapentin manages epilepsy by stabilizing irregular nerve activity in the brain and reducing seizure-inducing signals. This is achieved by targeting calcium channels to help avert seizures. For example, in May 2024, data from the U.S. government-run Centers for Disease Control and Prevention showed that roughly 2.9 million U.S. adults aged 18 and older reported having active epilepsy in 2022, a rise of 1.08% from 2021. Hence, the rising incidence of epilepsy is propelling the expansion of the gabapentin market.

How Is The Gabapentin Market Organized By Different Segments?

The gabapentin market covered in this report is segmented –

1) By Type: Generic, Branded

2) By Dosage Form: Tablet, Capsule, Oral Solution

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

4) By Application: Epilepsy, Neuropathic Pain, Restless Legs Syndrome, Other Applications

Subsegments:

1) By Generic: Gabapentin Immediate Release (IR), Gabapentin Extended Release (ER), Gabapentin Capsules, Gabapentin Tablets, Gabapentin Oral Solution

2) By Branded: Neurontin, Gralise, Horizant, Other Branded Formulations

What Current And Upcoming Trends Are Shaping The Gabapentin Market?

Key players in the gabapentin market are concentrating on the creation of enhanced formulations like bioequivalent tablets in an effort to increase the effectiveness of treatment and widen the range of therapies for neurological disorders. Bioequivalent tablets constitute generic medicines that can deliver a dose of the active compound into the bloodstream at the same rate and efficacy as their branded counterparts, ensuring comparable safety and therapeutic benefits. In March 2024, India’s Strides Pharma Science Limited released Gabapentin Tablets USP in 600 mg and 800 mg strengths, which secured approval from the United States Food & Drug Administration (USFDA). These launches served to broaden its neurology offerings in the US market. This pioneering gabapentin variant boasts increased bioavailability, precise dosage and patient-friendly administration and results in more consistent therapeutic outcomes, better control of symptoms, and higher convenience for long-term therapy. Gabapentin tablets USP, 600 mg, displays a versatile therapeutic potential by effectively managing an array of neurological ailments such as neuropathic pain and partial seizures, courtesy of its reliable dosage and established clinical efficacy.

Who Are The Primary Market Leaders In The Gabapentin Market?

Major companies operating in the gabapentin market are Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan Inc., Apotex Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Lupin Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited, Torrent Pharmaceuticals Ltd., Ipca Laboratories Private Limited, Granules India Limited, Medley Pharmaceuticals Limited, Wockhardt Limited, Epic Pharma LLC, Healing Pharma India Pvt. Ltd., Rochem International Inc., Accord Healthcare Limited, Strides Pharma Science Limited, Ascend Laboratories LLC

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/gabapentin-global-market-report

How Do Regional Dynamics Influence The Gabapentin Market Performance?

North America was the largest region in the gabapentin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gabapentin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=24544&type=smp

Browse Through More Reports Similar to the Global Gabapentin Market 2025, By The Business Research Company

Glycomic Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/glycomic-therapeutics-global-market-report

Glycopeptide Antibiotics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/glycopeptide-antibiotics-global-market-report

Antiglaucoma Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antiglaucoma-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model